EP2175844A1 - Urées à fluoroéthyle substitué en tant qu'agents adrénergiques alpha 2 - Google Patents
Urées à fluoroéthyle substitué en tant qu'agents adrénergiques alpha 2Info
- Publication number
- EP2175844A1 EP2175844A1 EP08771647A EP08771647A EP2175844A1 EP 2175844 A1 EP2175844 A1 EP 2175844A1 EP 08771647 A EP08771647 A EP 08771647A EP 08771647 A EP08771647 A EP 08771647A EP 2175844 A1 EP2175844 A1 EP 2175844A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pain
- compound
- atoms
- disease
- substituents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- n 0 or 1
- A is cyclohexyl having 0, 1, 2, 3, or 4 substituents wherein the substituents each independently consist of: a moiety consisting of from 0 to 8 carbon atoms, 0 or 1 nitrogen atoms, 0 or 1 oxygen atoms, 0 or 1 sulfur atoms, 0 to 3 fluorine atoms, and from 0 to 17 hydrogen atoms; F; Cl; Br; or I.
- substituents each independently consist of: a moiety consisting of from 0 to 8 carbon atoms, 0 or 1 nitrogen atoms, 0 or 1 oxygen atoms, 0 or 1 sulfur atoms, 0 to 3 fluorine atoms, and from 0 to 17 hydrogen atoms; F; Cl; Br; or I.
- Another embodiment is use of a compound disclosed herein in the manufacture of a medicament for the treatment of pain.
- the pain is chronic pain. "Chronic pain is pain that persists or recurs for [greater than] 3 months, persists [for greater than] 1 month after resolution of an acute tissue injury, or accompanies a nonhealing lesion.” (Online Merck Manual, Eighteenth Edition.) [7] In another embodiment the pain is neuropathic pain. "Neuropathic pain results from damage to or dysfunction of the peripheral or central nervous system.” (Online Merck Manual, Eighteenth Edition.)
- the pain is visceral pain.
- “Visceral pain comes from the abdominal viscera, which are innervated by autonomic nerve fibers and respond mainly to the sensations of distention and muscular contraction.” (Online Merck Manual, Eighteenth Edition.)
- the pain is allodynia. Allodynia is "pain due to a nonnoxious stimulus.” (Online Merck Manual, Eighteenth Edition.) [10] In another embodiment the pain is associated with muscle spasticity. [11] In another embodiment the pain is associated with diarrhea. [12] For the purposes of this disclosure, “treat,” “treating,” or “treatment” refers to the diagnosis, cure, mitigation, treatment, or prevention of disease or other undesirable condition.
- the compounds can be used to treat include hypertension, congestive heart failure, asthma, depression, glaucoma, elevated intraocular pressure, ischemic neuropathies, optic neuropathy, corneal pain, headache pain, migraine, cancer pain, back pain, irritable bowel syndrome pain, muscle pain, pain associated with diabetic neuropathy, the treatment of diabetic retinopathy, stroke, drug dependence, withdrawal symptoms, obsessive compulsive disorder, obesity, insulin resistance, diarrhea, diuresis, nasal congestions, spasticity, attention deficit disorder, psychoses, Crohn's disease, gastritis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and combinations thereof.
- reference to a compound should be construed broadly to include pharmaceutically acceptable salts, prodrugs, tautomers, alternate solid forms, and non-covalent complexes of a chemical entity of the depicted structure or chemical name.
- a pharmaceutically acceptable salt is any salt of the parent compound that is suitable for administration to an animal or human.
- a pharmaceutically acceptable salt also refers to any salt which may form in vivo as a result of administration of an acid, another salt, or a prodrug which is converted into an acid or salt.
- a salt is a chemical species having an ionic form of the compound, such as a conjugate acid or base, associated with a corresponding amount of counter-ions. Salts can form from or incorporate one or more deprotonated acidic groups (e.g. carboxylic acids), one or more protonated basic groups (e.g. amines), or both (e.g. zwitterions).
- a prodrug is a compound which is converted to a therapeutically active compound after administration to an animal or human. For example, conversion may occur by hydrolysis of an ester group or some other biologically labile group.
- Prodrug preparation is well known in the art. For example, "Prodrugs and Drug Delivery Systems,” which is a chapter in Richard B. Silverman, Organic Chemistry of Drug Design and Drug Action, 2d Ed., Elsevier Academic Press: Amsterdam, 2004, pp. 496- 557, provides further detail on the subject.
- Tautomers are isomers that are in rapid equilibrium with one another. For example, they may include a transfer of a proton, hydrogen atom, or hydride ion.
- the structures herein are intended to include, but are not limited to, the tautomeric forms shown below.
- Alternate solid forms are different solid forms than those that may result from practicing the procedures described herein.
- alternate solid forms may be polymorphs, different kinds of amorphous solid forms, glasses, and the like.
- Non-covalent complexes are complexes that may form between the compound and one or more additional chemical species that do not involve a covalent bonding interaction between the compound and the additional chemical species. They may or may not have a specific ratio between the compound and the additional chemical species. Examples might include solvates, hydrates, charge transfer complexes, and the like.
- n is 0 or 1
- the following compounds are possible.
- the substituents each independently consist of: a moiety consisting of from 0 to 8 carbon atoms, 0 or 1 nitrogen atoms, 0 or 1 oxygen atoms, 0 or 1 sulfur atoms, 0 to 3 fluorine atoms, and from 0 to 17 hydrogen atoms; F; Cl; Br; or I.
- substituents include, but are not limited to:
- Hydrocarbyl meaning a moiety consisting of carbon and hydrogen only, including, but not limited to:
- alkyl meaning hydrocarbyl having no double or triple bonds, including, but not limited to:
- linear alkyl e.g. methyl, ethyl, w-propyl, w-butyl, w-pentyl, w-hexyl, etc.
- branched alkyl e.g. ⁇ o-propyl, ?-butyl and other branched butyl isomers, branched pentyl isomers, etc.
- cycloalkyl e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
- combinations of linear, branched, and/or cycloalkyl e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
- alkenyl e.g. hydrocarbyl having 1 or more double bonds, including linear, branched, or cycloalkenyl
- alkynyl e.g. hydrocarbyl having 1 or more triple bonds, including linear, branched, or cycloalkenyl
- alkyl-CN such as -CH 2 -CN, -(CH 2 ) 2 -CN; -(CH 2 ) 3 -CN, and the like; [33] hydroxyalkyl, i.e. alkyl-OH, such as hydroxymethyl, hydroxyethyl, and the like; [34] ether substituents, including -O-alkyl, alkyl-O-alkyl, and the like; [35] thioether substituents, including -S-alkyl, alkyl-S-alkyl, and the like; [36] amine substituents, including -NH 2 , -NH-alkyl j -N-alky ⁇ alkyl 2 (i.e., alkyl 1 and alkyl 2 are the same or different, and both are attached to N), alkyl-NH 2 , alkyl-NH-alkyl, alkyl-N-alkyl 1 alkyl 2 , and the like;
- aminoalkyl meaning alkyl-amine, such as aminomethyl (-CH 2 -amine), aminoethyl, and the like; [38] ester substituents, including -CO 2 -alkyl, -CO 2 _phenyl, etc.; [39] other carbonyl substituents, including aldehydes; ketones, such as acyl (i.e. o
- hydrocarbyi an( j ⁇ jjj ⁇ g. m particular, acetyl, propionyl, and benzoyl substituents are contemplated;
- fluorocarbons or hydroflourocarbons such as -CF 3 , _CH 2 CF 3 , etc.; and [42] -CN;
- a substituent may be -F, -Cl, -Br, or -I.
- alkyl having from 1 to 8 carbon atoms is contemplated as a substituent.
- alkyl having from 1 to 4 carbon atoms is contemplated; [47] Substituents must be sufficiently stable to be stored in a bottle at room temperature under a normal atmosphere for at least 12 hours, or stable enough to be useful for any purpose disclosed herein.
- a substituent is a salt, for example of a carboxylic acid or an amine
- the counter-ion of said salt i.e. the ion that is not covalently bonded to the remainder of the molecule is not counted for the purposes of determining the number of atoms in a substituent.
- the salt -CO 2 Na + is a stable substituent consisting of 1 carbon atom and 2 oxygen atoms, i.e. sodium is not counted.
- the salt -NH(Me) 2 + Cl " is a stable substituent consisting of 1 nitrogen atom, 2 carbon atoms, and 7 hydrogen atoms, i.e. chlorine is not counted.
- the substituents are independently C 1 - 4 alkyl, C 1 -3 alkoxy, F, Cl, Br, I, or NH 2 .
- Ci_6 alkyl means alkyl having from 1 to 6 carbon atoms
- Ci_6 hydrocarbyl means hydrocarbyl having from 1 to 6 carbon atoms.
- Another embodiment is a compound having the formula
- R 1 is alkyl having from 1 to 6 carbon atoms.
- R 1 is w-propyl, i.e. -CH 2 CH 2 CH 3 .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne le traitement de la douleur chez les mammifères avec un composé de la formule (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94838907P | 2007-07-06 | 2007-07-06 | |
PCT/US2008/067748 WO2009009278A1 (fr) | 2007-07-06 | 2008-06-20 | Urées à fluoroéthyle substitué en tant qu'agents adrénergiques alpha 2 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2175844A1 true EP2175844A1 (fr) | 2010-04-21 |
Family
ID=39791193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08771647A Withdrawn EP2175844A1 (fr) | 2007-07-06 | 2008-06-20 | Urées à fluoroéthyle substitué en tant qu'agents adrénergiques alpha 2 |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2175844A1 (fr) |
WO (1) | WO2009009278A1 (fr) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6178724A (ja) * | 1984-09-25 | 1986-04-22 | Tetsuo Suami | 抗腫瘍剤 |
US6545182B2 (en) * | 2000-04-13 | 2003-04-08 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
US7709507B2 (en) * | 2006-05-17 | 2010-05-04 | Allergan, Inc. | Therapeutic fluoroethyl ureas |
-
2008
- 2008-06-20 EP EP08771647A patent/EP2175844A1/fr not_active Withdrawn
- 2008-06-20 WO PCT/US2008/067748 patent/WO2009009278A1/fr active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO2009009278A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009009278A1 (fr) | 2009-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2213743C2 (ru) | Производное тиенилазолилалкоксиэтанамина, способ его получения (варианты), фармацевтическая композиция, промежуточный продукт и способ его получения (варианты) | |
WO2007017092A1 (fr) | Derives amides d'acide 4-benzyloxy-benzoique substitue | |
JP2008515950A (ja) | 泌尿器系障害の処置用の冷メントール受容体−1(cmr−1)アンタゴニストとしての4−置換ベンジルオキシ−フェニルメチルアミド誘導体 | |
ZA200604395B (en) | Novel M3 Muscarinic Acetylcholine receptor antagonists | |
US8367835B2 (en) | Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same | |
RU2006113700A (ru) | Аминозамещенный этиламито-агонисты бэта2-адренергических рецепторов | |
EA001322B1 (ru) | Производные 2-(4-замещенного)-бензиламино-2-метилпропанамида | |
US11912680B2 (en) | Nitric oxide releasing prodrugs of MDA and MDMA | |
JP3839665B2 (ja) | 置換2−ベンジルアミノ−2−フェニル−アセトアミド化合物 | |
EP2491017B1 (fr) | Modulateurs du récepteur alpha-adrénergique | |
KR20080089413A (ko) | 카나비노이드 cb1 수용체 조절자로서의4,5-디하이드로-(1h)-피라졸 유도체 | |
US8080570B2 (en) | α2B and α2C agonists | |
WO2007080109A1 (fr) | Dérivés de benzyloxyphénylméthylurée substitués | |
US20230227407A1 (en) | Dimethyltryptamine analogues as nitric oxide delivery drugs | |
WO2009009278A1 (fr) | Urées à fluoroéthyle substitué en tant qu'agents adrénergiques alpha 2 | |
US20110028559A1 (en) | Substituted fluoroethyl ureas as alpha 2 adrenergic agents | |
WO2017022733A1 (fr) | Dérivé de pipérazine | |
MX2011001846A (es) | Nuevos derivados de piperidina-4-acetamida y su uso como inhibidores de la reabsorcion del neurotransmisor de monoamina. | |
EP2188261A1 (fr) | Composés thérapeutiques | |
US20200360304A1 (en) | Beta-2 selective adrenergic receptor agonists | |
JP2017521392A (ja) | 化合物、医薬組成物、及び神経変性疾患の治療におけるそれらの使用 | |
WO2015046405A1 (fr) | Analgésique | |
MX2011001847A (es) | Nuevos derivados de piperidina-propionamida y su uso como inhibidores de la reabsorcion del neurotransmisor de monoamina. | |
EP2188262A1 (fr) | Carbocycles fusionnés substitués par hétérocyclyle utiles dans le traitement d'affections telles que le glaucome et la douleur | |
EP1497256B1 (fr) | Composes de 1,5-diaminopentane-3-ol substitues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100205 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20120102 |